

Cardio IQ®

Advanced Cardiovascular Testing

Uncover Hidden Risk for Heart Attack and Stroke




For Physicians

Are traditional risk factors enough when managing cardiovascular disease?


Heart disease continues to be the leading cause of death in the U.S.¹

Evolving guidelines continue to focus on traditional factors to manage cardiovascular risk




Residual cardiovascular risk is still significant despite managing traditional risk factors

LDL-C Levels <100mg/dL




Studies show that LDL-C cholesterol levels were often not predictive of coronary artery disease (CAD). In a population of over 200,000 patients hospitalized with CAD, almost half had LDL-C levels <100 mg/dL.²

1st CHD Event



The AHA Get-With-The-Guidelines® initiative analysis² revealed that a substantial proportion of patients with CHD events were well within guideline-recommended targets for Lipid Panel values.

Recurrent CHD



Even after statin therapy, recent data suggests that residual risk still exists in many patients.³

Quest Diagnostics can help improve the management of cardiovascular patients

Gain deeper insights into the individual residual risks of your patients

Uncovering hidden risk may benefit those patients with traditional cardiovascular disease (CVD) risk factors:

- Age (men >45 years; postmenopausal women)
- Family history of premature onset of CVD
- Unhealthy diet, excessive alcohol intake, smoking, and stress
- Obesity
- Low HDL-C

Additional risk stratification may be considered for:

- $\geq 5\%$ Estimated ASCVD Risk
- Established cardiovascular disease, hypertension, or dyslipidemia
- Diabetes
- Metabolic syndrome




Patient types are meant to be illustrative and should not be considered a comprehensive representation.

Identifying residual risk with emerging biomarkers

Biomarkers have been shown to help identify risk and thus have been adopted by several guidelines and societies.⁴⁻⁶



Lipoprotein Risk Factors

Risk Factor	Impact on Cardiovascular Disease (CVD)
LDL Particle Number	The Quebec Cardiovascular Study was the first to demonstrate that heart attack can occur when LDL particle number is high and low-density lipoprotein level is low. Greater numbers of cholesterol-containing particles in the blood means more cholesterol deposition in plaque and therefore an increased risk for heart attack.
HDL Subclasses	A low level of large HDL particles may reduce the efficacy of the reverse cholesterol transport process. The large HDL subclass was identified in the Malmö Diet and Cancer Study to be inversely correlated with CHD risk.
LDL Subclasses	Small LDL subclass particles cause plaque buildup to progress much faster because they enter the artery wall more easily than large LDL particles. A predominance of smaller LDL particles, referred to as Pattern B lipid phenotype, represents an atherogenic lipid profile that is associated with CVD.
ApoB	ApoB is the primary apolipoprotein attached to all atherogenic particles. It is involved in the metabolism and transport of lipids. A high ApoB number indicates increased risk for heart disease.
Lp(a)	Lipoprotein(a) is an inherited protein that is attached to LDL. High levels of lipoprotein(a) increase risk of coagulation and contribute to atherosclerosis.



Inflammation Risk Factors

Risk Factor	Impact on Cardiovascular Disease (CVD)
MPO (Myeloperoxidase)	MPO is a marker of vascular-specific inflammation within the vessel lumen. Elevations occur due to white blood cell activation in response to fissures, erosions, or degradation of the fibrous cap. MPO is actively involved in atherosclerosis and is considered a near-term risk marker for cardiovascular events.
Lp-PLA ₂ (Lipoprotein-Associated Phospholipase A ₂)	Lp-PLA ₂ measures disease activity within the artery wall below the collagen or calcified cap due to activation of macrophages. The AHA and AACE guidelines list Lp-PLA ₂ as a strong and independent predictor of ASCVD events and may be valuable in identifying patients at increased CVD risk.
hs-CRP (High Sensitivity C-Reactive Protein)	The hs-CRP test is a highly sensitive quantification of CRP, an acute-phase protein released into the blood by the liver during inflammation. hs-CRP is a well-documented clinical marker of cardiac-related inflammation. 2013 ACC/AHA guidelines state hs-CRP may be useful in the evaluation of those at moderate risk for heart disease and determining whether or not more intensive treatment is warranted.
ADMA/SDMA (Asymmetric/Symmetric Dimethylarginine)	ADMA is an L-arginine derivative that inhibits nitric oxide production, an early manifestation of endothelial dysfunction and CVD progression. SDMA is a structural isomer of ADMA, but is primarily excreted in the urine and can indicate reduced renal function.
OxLDL (Oxidized LDL)	OxLDL measures oxidative protein damage of the ApoB subunit on LDL cholesterol. Elevated OxLDL promotes vascular inflammation and is associated with increased risk of metabolic syndrome, CAD, and CHD.
F ₂ -IsoPs (F ₂ -Isoprostanes)	Urinary F ₂ -Isoprostanes (F ₂ -IsoPs) measure oxidative stress in the body, primarily due to lifestyle risk factors. F ₂ -IsoPs contribute to CVD progression through increased risk of vasoconstriction, platelet aggregation, and thrombus formation.



Managing residual risk with advanced insights

Advanced cardiovascular testing provides actionable information to individualize treatment options:

- Initiate/intensify statin therapy
- Identify opportunities for adjunct therapy
- Set diet, exercise, and lifestyle targets

The Cardio IQ® Enhanced Lab Report

Offering key insights for individualized patient treatment

Test results are shown in “Optimal,” “Moderate,” or “High” risk categories, and are **color-coded to display progressive risk** values.

Historic results of previous tests are provided with the Cardio IQ report to help monitor patient progress.

This example represents the resulting report for an order of Advanced Lipid Panel with Inflammation, which includes:

Cardio IQ Lipid Panel with Reflex to Direct LDL

Cardio IQ Ion Mobility

Cardio IQ Apo B

Cardio IQ Lp(a)

Cardio IQ hs-CRP

Cardio IQ Lp-PLA₂

Test Name	Units	Result and Risk Category			Result From	Risk Category Ranges		
		Optimal	Moderate	High		Optimal	Moderate	High
Lipid Panel Lab: EZ								
CHOLESTEROL, TOTAL	mg/dL	166				<200	200-239	>=240
HDL CHOLESTEROL	mg/dL	61				>=40	N/A	<40
TRIGLYCERIDES	mg/dL	81				<150	150-199	>=200
LDL-CHOLESTEROL	mg/dL	89				<100	100-129	>129
CHOL/HDLC RATIO	calc	2.7				<=3.5	3.6-5.0	>5.0
NON-HDL CHOLESTEROL	mg/dL	105				<130	130-159	>159
Lipoprotein Subfractions Lab: EZ								
LDL PARTICLE NUMBER	nmol/L		1203			<1138	1138-1409	>1409
LDL SMALL	nmol/L			236		<142	142-219	>219
LDL MEDIUM	nmol/L			373		<215	215-301	>301
HDL LARGE	nmol/L	9454				>6729	6729-5353	<5353
Apolipoproteins Lab: EZ								
APOLIPOPROTEIN B	mg/dL		80			<80	80-119	>=120
LIPOPROTEIN (a)	nmol/L		77			<75	75-125	>125
Inflammation Lab: EZ								
HS CRP	mg/L			4.5		<1.0	1.0-3.0	>3.0
LP PLA ₂	nmol/min/mL	120				<=123	N/A	>123

Test Results	Relative Risk	Treatment Options ^{‡§}	Goal ^{†§}
Elevated LDL Cholesterol	1.6x ⁷	<ul style="list-style-type: none"> Diet and exercise Statins, ezetimibe, bile acid sequestrants (BAS), PCSK9 inhibitors 	LDL Cholesterol <100 mg/dL LDL Cholesterol reduction 30% to <50% Moderate-intensity statin dose group LDL Cholesterol reduction >50% High-intensity statin dose group
Elevated Triglycerides	1.7–4.0x ⁷	<ul style="list-style-type: none"> Diet and exercise Fibrates, high-dose omega-3 fatty acids, nicotinic acid 	Triglycerides <150 mg/dL
Elevated LDL Particle Number	1.4–2.3x ^{8*,9,10}	<ul style="list-style-type: none"> Diet and exercise Statins, ezetimibe, BAS, PCSK9 inhibitors 	<1138 nmol/L
Elevated Small LDL Particles	1.3–2.1x ^{8*,9,10} 1.5x (sdLDL) ¹¹	<ul style="list-style-type: none"> Diet and exercise Address excess LDL-P or ApoB Consider therapies to address insulin resistance (e.g., Metformin) 	Small <142 nmol/L sdLDL ≤40.0 mg/dL
Elevated Medium LDL Particles	1.4–2.2x ^{8*,9,10}	<ul style="list-style-type: none"> Diet and exercise Address excess LDL-P or ApoB Consider therapies to address insulin resistance (e.g., Metformin) 	Medium <215 nmol/L
Suboptimal Large HDL	1.8x (Large HDL) ^{8*} 1.9x (HDL2b) ¹²	<ul style="list-style-type: none"> Diet and exercise May consider nicotinic acid 	Large HDL >6729 nmol/L HDL2b >26% (Males); HDL2b >28% (Females)
Elevated ApoB Particles	2.0–2.5x ¹³	<ul style="list-style-type: none"> Diet and exercise Statins, ezetimibe, BAS, PCSK9 inhibitors 	ApoB <80 mg/dL
Elevated Lp(a)	1.5–5.3x ¹⁴	<ul style="list-style-type: none"> More aggressive lowering of LDL[‡] or ApoB Consider nicotinic acid 	Lp(a) <75 nmol/L
Elevated F ₂ -Isoprostanes	1.8–2.6x ^{15,16}	<ul style="list-style-type: none"> Diet, exercise, and smoking cessation Assure optimal LDL[‡] levels 	F ₂ -Isoprostanes <0.86 ng/mg creatinine
Elevated OxLDL	3.5–4.3x ^{17,18}	<ul style="list-style-type: none"> Diet and exercise Address LDL[‡] and insulin sensitivity 	OxLDL <60 U/L
Elevated ADMA/SDMA	1.4x (ADMA) ¹⁹	<ul style="list-style-type: none"> Diet and exercise Statins Assure major CVD risk factor goals are achieved 	ADMA <100 ng/mL SDMA 73–135 mg/mL
Elevated hs-CRP	2.3–2.9x ^{20,21}	<ul style="list-style-type: none"> Diet and exercise Address etiology Consider subclinical CAD or insulin resistance 	hs-CRP <1 mg/L
Elevated Lp-PLA ₂	2.0x ^{22†}	<ul style="list-style-type: none"> Diet and exercise More aggressive lowering of LDL[‡] or ApoB Consider omega-3 fatty acids 	Lp-PLA ₂ ≤123 nmol/min/mL
Elevated MPO	2.0–2.4x ^{23,24†}	<ul style="list-style-type: none"> Diet and exercise Assure major CVD risk factor goals are achieved 	MPO <470 pmol/L

* Expected risk of highest tertile versus lowest tertile assuming measure is normally distributed and risk increases linearly.

† The risk associated with elevated Lp-PLA₂ or MPO levels is substantially increased in patients when either Lp-PLA₂²² or MPO²³ is elevated with CRP.

‡ Includes LDL-C and LDL-P.

§ The treatment considerations are provided for informational purposes only and are not intended as medical advice. A physician's test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient. For more information on treatment options and goals per test, please see the Test Guide and/or Test Summary posted within the specific test's section at QuestDiagnostics.com/TestCenter.

Ordering Information

Test Name	Test Code*	CPT Code(s)*
Cardio IQ Advanced Lipid Panel with Inflammation**	94220(X)	80061, 83704, 82172, 83695, 86141, 83698
Includes:		
Cardio IQ Lipid Panel with Reflex to Direct LDL**	92061(X)	80061
Cardio IQ Lipoprotein Fractionation, Ion Mobility	91604(X)	83704
Cardio IQ Apolipoprotein B	91726(X)	82172
Cardio IQ Lipoprotein (a)	91729(X)	83695
Cardio IQ hs-CRP	91737(X)	86141
Cardio IQ Lp-PLA ₂	94218(X)	83698
Cardio IQ MPO	92814	83876
Cardio IQ ADMA/SDMA	94153	82542
Cardio IQ OxLDL	92769	83520
Cardio IQ F ₂ -Isoprostane/Creatinine	92771	82542/82570

Other cardiometabolic testing

We offer additional advanced CVD tools for personalization of risk management in your patients. Options include deeper insight into functional areas important in managing CVD risk patients, such as inflammation status, myocardial stress, cardiometabolic state, and cardiovascular genetics.

*Test codes may vary by location. Please contact your laboratory for more information. The CPT codes provided are based on AMA Guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Lipid Panel components may be ordered separately: Cholesterol, Total 91717(X)/334 (CPT 82465); Triglycerides 91718(X)/896 (CPT 84478); HDL Cholesterol 91719(X)/608 (CPT 83718). If triglyceride result is >400 mg/dL, Direct LDL Cholesterol will be performed at an additional charge (CPT 83721).



For more information, contact your Quest Diagnostics sales representative or visit us at QuestDiagnostics.com/Education.

References

- Benjamin EJ, Virani SS, Callaway CW, et al. On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2018 update: a report from the American Heart Association. *Circulation*. DOI: 10.1161/CIR.0000000000000558.
- Sachdeva A, Cannon CP, Deedwania PC, et al. on behalf of the Get-With-The-Guidelines (GWTG) Steering Committee and Hospitals. *AHJ*. 2009;157:111-117.e2.(1)
- Reith C and Armitage J. Management of residual risk after statin therapy. *Atherosclerosis*. 2016;245:161-170
- Third Report of the National Cholesterol Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. *Circulation*. 2002;106(25):3143-3412.
- Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. *J Clin Lipidol*. 2011;5:338-367.
- Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement of the American Diabetes Association and the American College of Cardiology Foundation. *Diabetes Care*. 2008;31(4):811-822.
- Miller M, Stone N, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circ*. 2011;123:2292-2333.
- Musunuru K, Orho-Melander M, Caulfield MP, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. *Arterioscler Thromb Vasc Biol*. 2009;29:1975-80.
- Melander O, Shiffman D, Caulfield MP, et al. Low-density lipoprotein particle number is associated with cardiovascular events among those not classified into statin benefit groups. *J Am Coll Cardiol*. 2015;65(23):2571-2573.
- Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo. The justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (jupiter) trial. *Circulation*. 2015;132:2220-2229.
- Hoogeveen R, Gaubatz J, Sun W, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease. *Arterioscler Thromb Vasc Biol*. 2014;34:00-00.
- Williams PT and Feldman DE. Prospective study of coronary heart disease vs HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. *Atherosclerosis*. 2011;214(1):196-202.
- Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. *Circ Cardiovasc Qual Outcomes*. 2011;4:337-345.
- Nordesgaard B, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010;31:2844-2853.
- Kim JY, Hyun YJ, Jang Y, et al. Lipoprotein-associated phospholipase A₂ activity is associated with coronary artery disease markers of oxidative stress: a case-control study. *Am J Clin Nutr*. 2008;88:630-637.
- Roest M, Voorbij HAM, Van der Schouw YT, et al. High levels of urinary F₂-isoprostanes predict cardiovascular mortality in postmenopausal women. *J Clin Lipidol*. 2008;2:298-303.
- Meisinger C, Baumert J, Khuseynova N, et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. *Circulation*. 2005;112:651-657.
- Holvoet P, De Keyser D, and Jacobs DR. Oxidized LDL and the metabolic syndrome. *Future Lipidol*. 2008;3(6):637-649.
- Willeit P, Freitag DF, Laukkanen JA, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. *J Am Heart Assoc*. 2015;4:e001833.
- Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med*. 1997;336:973-979.
- Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med*. 2002;347:1557-1565.
- Heslop CL, Frohlich JJ, and Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. *J Am Coll Cardiol*. 2010;55:1102-1109.
- Cushman M, Judd S, Kissela, et al. Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) activity and coronary heart disease risk in a biracial cohort: The reasons for geographic and racial differences in stroke (REGARDS) Cohort. *Atherosclerosis*. 2015;241:e1-e31. [Abstract]
- Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. *J Am Coll Cardiol*. 2009;2(9):1093-1099.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—© and ™—are the property of their respective owners. ©2018 Quest Diagnostics Incorporated. All rights reserved. MD46 6/2018